We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Wearable Defibrillator Reduces Mortality after Heart Attack

By HospiMedica International staff writers
Posted on 21 Mar 2018
A defibrillator vest allows physicians time to assess and optimize medical therapy, and protects patients at risk for sudden cardiac arrest (SCA).

The Zoll Medical (Chelmsford, MA, US) LifeVest Wearable Cardioverter Defibrillator (WCD) is a lightweight vest (worn under clothing) that continuously monitors a patient’s heart with dry, non-adhesive sensing electrodes; if a life-threatening heart rhythm is detected, the device alerts the patient prior to delivering a treatment shock, allowing a conscious patient to delay treatment. If the patient becomes unconscious, the device releases a special gel over the therapy electrodes, delivering an electrical shock to restore normal rhythm.

Image: The LifeVest WCD (Photo courtesy of Zoll Medical).
Image: The LifeVest WCD (Photo courtesy of Zoll Medical).

The LifeVest WCD is prescribed for patients at risk of SCA, including those with a low ejection fraction (EJ), patients who have recently suffered a myocardial infarct (MI), those with a new diagnosis of heart failure (HF), and post-coronary revascularization patients. In a recent study that enrolled 2,302 post-MI patients in four countries, the LifeVest WCD, together with guideline directed medical therapy (GDMT) reduced total mortality by 36% in the first 90 days following MI, compared to GDMT alone. The study was presented American College of Cardiology (ACC) 67th annual scientific session, held during March 2018 in Orlando (FL, USA).

“In addition to the current best practices in medicine which includes GDMT, use of the LifeVest WCD can further reduce mortality in patients with a low EF,” said Kent Volosin, MD, vice president of medical and clinical affairs for ZOLL LifeVest. “The totality of clinical evidence supporting use of the WCD, along with guideline recommendations, underscores the need to evaluate all patients for sudden cardiac death risk and discuss WCD therapy with patients and their families through a shared decision-making approach.”

A companion online patient management system, The LifeVest Network, allows clinicians to monitor patient data downloaded from the LifeVest WCD, which can then be accessed online. The LifeVest Network also allows the physician to monitor patients efficiently and be notified of events recorded by the LifeVest device. The physician can log in and review patient information, or set up alerts and be notified when a patient has clinical information for review.


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
12-Channel ECG
CM1200B
New
Mini C-arm Imaging System
Fluoroscan InSight FD
New
Monitor Cart
Tryten S5

Latest Critical Care News

Ablation Treatment Better Than Medication for Heart Attack Survivors

Cranial Accelerometry Headset Enables Timely and Accurate Prehospital Detection of LVO Strokes

Ingestible Capsule Pump Drugs Directly into Walls of GI Tract